New drug combo aims to shrink Hard-to-Treat tumors

NCT ID NCT07694765

Not yet recruiting Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LM-364 (an experimental drug) and tislelizumab (an immunotherapy)
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. Success in this trial does not guarantee broader benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Care Wollongong Hospital

Wollongong, New South Wales, Australia

Contact
Icon Cancer Centre South Brisbane

Brisbane, Queensland, Australia

Contact
Macquarie University

North Ryde, New South Wales, Australia

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.